Published in J Natl Compr Canc Netw on February 01, 2009
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Bending the cost curve in cancer care. N Engl J Med (2011) 5.02
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol (2014) 1.62
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat (2010) 1.59
Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines. JAMA Oncol (2016) 1.48
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res (2010) 1.47
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res (2012) 1.21
Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol (2011) 1.18
Emerging treatments for choroidal metastases. Surv Ophthalmol (2011) 1.18
Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA (2011) 1.15
Current approaches and challenges in monitoring treatment responses in breast cancer. J Cancer (2014) 1.13
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2013) 1.12
Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat (2011) 1.08
Age, comorbidity, and breast cancer severity: impact on receipt of definitive local therapy and rate of recurrence among older women with early-stage breast cancer. J Am Coll Surg (2011) 1.07
Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol (2014) 1.05
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther (2013) 1.01
Current approaches and challenges in early detection of breast cancer recurrence. J Cancer (2014) 1.00
Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol (2013) 0.97
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res (2009) 0.97
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br J Cancer (2011) 0.94
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist (2011) 0.94
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat (2011) 0.93
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol (2010) 0.92
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat (2011) 0.91
Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older. Cancer Prev Res (Phila) (2012) 0.91
Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer. PLoS One (2014) 0.90
Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomarkers Prev (2013) 0.90
Influence of surgical margins on the outcome of breast cancer patients: a retrospective analysis. World J Surg (2014) 0.90
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther (2010) 0.89
TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion. Int J Cancer (2013) 0.89
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy. BMC Med Inform Decis Mak (2014) 0.89
Synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature. Case Rep Oncol Med (2012) 0.88
Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res (2013) 0.88
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer (2013) 0.87
The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene (2013) 0.86
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care (Basel) (2010) 0.86
Breast MRI in community practice: equipment and imaging techniques at facilities in the Breast Cancer Surveillance Consortium. J Am Coll Radiol (2010) 0.85
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLoS One (2012) 0.83
HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics (2011) 0.83
Axillary lymph node dissection for breast cancer utilizing Harmonic Focus®. World J Surg Oncol (2011) 0.83
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer (2012) 0.83
Physicians' influence on breast cancer patient compliance. Ger Med Sci (2014) 0.82
Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women's Cancer Initiative - Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol (2012) 0.82
Therapeutic mammaplasty for breast cancer: oncological and aesthetic outcomes. World J Surg (2013) 0.82
The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist (2012) 0.81
Multi-state models for investigating possible stages leading to bipolar disorder. Int J Bipolar Disord (2015) 0.81
Quality of cancer follow-up care: a focus on Latina breast cancer survivors. J Cancer Surviv (2014) 0.81
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer (2010) 0.81
Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol (2010) 0.81
Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. Br J Cancer (2012) 0.81
Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management. Ann Surg Oncol (2015) 0.81
Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol (2013) 0.80
Feasibility of sentinel lymph node biopsy in breast cancer patients clinically suspected of axillary lymph node metastasis on preoperative imaging. World J Surg Oncol (2013) 0.80
A Case Report of Male Occult Breast Cancer First Manifesting as Axillary Lymph Node Metastasis With Part of Metastatic Mucinous Carcinoma. Medicine (Baltimore) (2015) 0.80
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging. Curr Breast Cancer Rep (2011) 0.79
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer. Breast Care (Basel) (2010) 0.79
[(89)Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Mol Imaging Biol (2016) 0.79
Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Arch (2013) 0.78
Adjuvant chemotherapy for breast cancer in patients with schizophrenia. Oncol Lett (2012) 0.78
Predictors for contralateral prophylactic mastectomy in breast cancer patients. Int J Clin Exp Pathol (2015) 0.77
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One (2012) 0.77
Sentinel lymph node mapping in early stage of endometrial and cervical cancers. J Res Med Sci (2015) 0.77
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul) (2014) 0.77
DNA methylation profiling distinguishes three clusters of breast cancer cell lines. Chem Biodivers (2012) 0.76
Population and target considerations for triple-negative breast cancer clinical trials. Biomark Med (2013) 0.76
Quality of post-treatment surveillance of early stage breast cancer in Texas. Surgery (2013) 0.76
Bootcamp during neoadjuvant chemotherapy for breast cancer: a randomized pilot trial. Breast Cancer (Auckl) (2012) 0.76
Effects of physical activity on systemic oxidative/DNA status in breast cancer survivors. Oncol Lett (2016) 0.75
Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. J Breast Cancer (2013) 0.75
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result. J Community Support Oncol (2015) 0.75
Information Needs of Older Women With Early-Stage Breast Cancer When Making Radiation Therapy Decisions. Int J Radiat Oncol Biol Phys (2017) 0.75
ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. PLoS One (2014) 0.75
The status of antioxidants, malondialdehyde and some trace elements in serum of patients with breast cancer. Caspian J Intern Med (2016) 0.75
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. Cancer Res Treat (2016) 0.75
Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int (2014) 0.75
The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment. Oncology (2016) 0.75
Pre and post radiotherapy serum oxidant/antioxidant status in breast cancer patients: Impact of age, BMI and clinical stage of the disease. Rep Pract Oncol Radiother (2016) 0.75
Gynecologic care for breast cancer survivors: assisting in the transition to wellness. Am J Obstet Gynecol (2011) 0.75
Management of Malignant Pericardial Effusion. J Adv Pract Oncol (2015) 0.75
Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1-2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram. World J Surg (2015) 0.75
Strategies for Appropriate Patient-centered Care to Decrease the Nationwide Cost of Cancers in Korea. J Prev Med Public Health (2017) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology (2004) 5.37
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol (2005) 5.23
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 4.61
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 4.47
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45